Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Wayne L Furman. (2021) Monoclonal Antibody Therapies for High Risk Neuroblastoma. Biologics: Targets and Therapy 15, pages 205-219.
Read now
Read now
Michelle E Keyel & C Patrick Reynolds. (2019) Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy. Biologics: Targets and Therapy 13, pages 1-12.
Read now
Read now
Ina Mueller, Karoline Ehlert, Stefanie Endres, Lena Pill, Nikolai Siebert, Silke Kietz, Penelope Brock, Alberto Garaventa, Dominique Valteau-Couanet, Evelyne Janzek, Norbert Hosten, Andreas Zinke, Winfried Barthlen, Emine Varol, Hans Loibner, Ruth Ladenstein & Holger N. Lode. (2018) Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD2 antibody ch14.18/CHO. mAbs 10:1, pages 55-61.
Read now
Read now
Irene Y. Cheung, Brian H. Kushner, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts & Nai-Kong V. Cheung. (2017) Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival. OncoImmunology 6:11.
Read now
Read now
Nikolai Siebert, Maxi Zumpe, Madlen Jüttner, Sascha Troschke-Meurer & Holger N. Lode. (2017) PD-1 blockade augments anti-neuroblastoma immune response induced by anti-GD2 antibody ch14.18/CHO. OncoImmunology 6:10.
Read now
Read now
Sameer Sait & Shakeel Modak. (2017) Anti-GD2 immunotherapy for neuroblastoma. Expert Review of Anticancer Therapy 17:10, pages 889-904.
Read now
Read now
Mark A. Applebaum, Ami V. Desai, Julia L. Glade Bender & Susan L. Cohn. (2017) Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs 5:4, pages 355-368.
Read now
Read now
Beate Hintersteiner, Nico Lingg, Peiqing Zhang, Susanto Woen, Kong Meng Hoi, Stefan Stranner, Susanne Wiederkum, Oliver Mutschlechner, Manfred Schuster, Hans Loibner & Alois Jungbauer. (2016) Charge heterogeneity: Basic antibody charge variants with increased binding to Fc receptors. mAbs 8:8, pages 1548-1560.
Read now
Read now
Nikolai Siebert, Christian Jensen, Sascha Troschke-Meurer, Maxi Zumpe, Madlen Jüttner, Karoline Ehlert, Silke Kietz, Ina Müller & Holger N. Lode. (2016) Neuroblastoma patients with high-affinity FCGR2A, -3A and stimulatory KIR 2DS2 treated by long-term infusion of anti-GD2 antibody ch14.18/CHO show higher ADCC levels and improved event-free survival. OncoImmunology 5:11.
Read now
Read now
Articles from other publishers (30)
Holger N. Lode, Karoline Ehlert, Stephanie Huber, Sascha Troschke-Meurer, Nikolai Siebert, Maxi Zumpe, Hans Loibner & Ruth Ladenstein. (2023) Long-term, continuous infusion of single-agent dinutuximab beta for relapsed/refractory neuroblastoma: an open-label, single-arm, Phase 2 study. British Journal of Cancer 129:11, pages 1780-1786.
Crossref
Crossref
Paul T Kennedy, Demetra Zannoupa, Meong Hi Son, Lekh N Dahal & John F Woolley. (2023) Neuroblastoma: an ongoing cold front for cancer immunotherapy. Journal for ImmunoTherapy of Cancer 11:11, pages e007798.
Crossref
Crossref
Nikolai Siebert, Maxi Zumpe, Christian Heinrich Schwencke, Simon Biskupski, Sascha Troschke-Meurer, Justus Leopold, Alexander Zikoridse & Holger N. Lode. (2023) Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta. Cancers 15:13, pages 3317.
Crossref
Crossref
Karsten Nysom, Andrea Gomez Morad, Margarida Simão Rafael, Judith Zier, Araz Marachelian, Tanya Watt & Daniel A. Morgenstern. (2023) Pain mitigation and management strategies for anti‐GD2 infusions: An expert consensus. Pediatric Blood & Cancer 70:5.
Crossref
Crossref
Sascha Troschke-Meurer, Maxi Zumpe, Lena Meißner, Nikolai Siebert, Piotr Grabarczyk, Hannes Forkel, Claudia Maletzki, Sander Bekeschus & Holger N. Lode. (2023) Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models. Cancers 15:3, pages 904.
Crossref
Crossref
Julia Balaguer, Laura García Hidalgo, Raquel Hladun, Catalina Márquez Vega & Vanesa Pérez Alonso. (2022) Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma. Targeted Oncology 18:1, pages 77-93.
Crossref
Crossref
Xin‐Yuan Liu, Yi‐Li Chen, Guo‐Jian Liu, Xiang‐Nan Deng, Yue Cui, Jie Tan, Xing‐Chen Dong, Hua‐Ying Li, Gan‐Jun Chen, Zhi‐Min Ou & Chun‐He Wang. (2022) Development of a variant of dinutuximab with enhanced antitumor efficacy and reduced induction of neuropathic pain. FEBS Open Bio 12:9, pages 1644-1656.
Crossref
Crossref
Aleksandra Wieczorek, Carla Manzitti, Alberto Garaventa, Juliet Gray, Vassilios Papadakis, Dominique Valteau-Couanet, Katarzyna Zachwieja, Ulrike Poetschger, Ingrid Pribill, Stefan Fiedler, Ruth Ladenstein & Holger N. Lode. (2022) Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials. Cancers 14:8, pages 1919.
Crossref
Crossref
Hemant Kumar & Rachna Gupta. (2022) Anti-Disialoganglioside-2 Monoclonal Antibodies as an Emerging Therapeutic Approach in Treatment of High-Risk Neuroblastoma. Current Pharmacology Reports 8:2, pages 112-120.
Crossref
Crossref
Godfrey Chi-Fung Chan & Carol Matias Chan. (2022) Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma. Biomolecules 12:3, pages 358.
Crossref
Crossref
Stefano Mastrangelo, Serena Rivetti, Silvia Triarico, Alberto Romano, Giorgio Attinà, Palma Maurizi & Antonio Ruggiero. (2021) Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients. International Journal of Molecular Sciences 22:23, pages 12648.
Crossref
Crossref
I. V. Kazantsev, A. G. Gevorgyan, T. V. Yukhta, D. A. Drozdovskaya, P. S. Tolkunova, E. V. Goncharova, A. V. Kozlov, M. S. Golenkova, A. N. Galimov, O. I. Bogdanova, Yu. A. Punanov, A. D. Kulagin & L. S. Zubarovskaya. (2021) Immunotherapy by anti-GD2 antibodies in patients with primary high-risk neuroblastoma, primary resistant and relapsed disease: Raisa Gorbacheva Memorial Research Institute of Children Oncology, Hematology and Transplantation, First Pavlov State Medical University of St. Petersburg experience. Russian Journal of Pediatric Hematology and Oncology 8:3, pages 14-29.
Crossref
Crossref
Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desireé Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang & Patrick Schlegel. (2021) Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment. Frontiers in Immunology 12.
Crossref
Crossref
Alice L. Yu, Andrew L. Gilman, M. Fevzi Ozkaynak, Arlene Naranjo, Mitchell B. Diccianni, Jacek Gan, Jacquelyn A. Hank, Ayse Batova, Wendy B. London, Sheena C. Tenney, Malcolm Smith, Barry L. Shulkin, Marguerite Parisi, Katherine K. Matthay, Susan L. Cohn, John M. Maris, Rochelle Bagatell, Julie R. Park & Paul M. Sondel. (2021) Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research 27:8, pages 2179-2189.
Crossref
Crossref
Nadiya Bayeva, Erin Coll & Olga Piskareva. (2021) Differentiating Neuroblastoma: A Systematic Review of the Retinoic Acid, Its Derivatives, and Synergistic Interactions. Journal of Personalized Medicine 11:3, pages 211.
Crossref
Crossref
Esther Coronado, Yania Yañez, Enrique Vidal, Luis Rubio, Francisco Vera‐Sempere, Antonio José Cañada‐Martínez, Joaquín Panadero, Adela Cañete, Ruth Ladenstein, Victoria Castel & Jaime Font de Mora. (2021) Intratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets. Molecular Oncology 15:2, pages 364-380.
Crossref
Crossref
Celina L. Szanto, Annelisa M. Cornel, Saskia V. Vijver & Stefan Nierkens. (2020) Monitoring Immune Responses in Neuroblastoma Patients during Therapy. Cancers 12:2, pages 519.
Crossref
Crossref
Heinz Kohler, Anastas Pashov & Thomas Kieber-Emmons. (2019) The Promise of Anti-idiotype Revisited. Frontiers in Immunology 10.
Crossref
Crossref
Julie Voeller & Paul M. Sondel. (2019) Advances in Anti-GD2 Immunotherapy for Treatment of High-risk Neuroblastoma. Journal of Pediatric Hematology/Oncology 41:3, pages 163-169.
Crossref
Crossref
Brian H. Kushner, Irene Y. Cheung, Shakeel Modak, Ellen M. Basu, Stephen S. Roberts & Nai-Kong Cheung. (2018)
Humanized 3F8 Anti-G
D2
Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma
. JAMA Oncology 4:12, pages 1729.
Crossref
Crossref
Nikolai Siebert, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Juliet Gray, Alberto Garaventa, Carla Manzitti, Shifra Ash, Thomas Klingebiel, James Beck, Victoria Castel, Dominique Valteau-Couanet, Hans Loibner, Ruth Ladenstein & Holger Lode. (2018) Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers 10:10, pages 387.
Crossref
Crossref
Kate McKeage & Katherine A. Lyseng-Williamson. (2018) Dinutuximab beta in high-risk neuroblastoma: a profile of its use. Drugs & Therapy Perspectives 34:7, pages 281-287.
Crossref
Crossref
Kiraz Ceylan, Luciana J. Jahns, Bjoern N. Lode, Karoline Ehlert, Silke Kietz, Sascha Troschke‐Meurer, Nikolai Siebert & Holger N. Lode. (2018)
Inflammatory response and treatment tolerance of long‐term infusion of the anti‐GD
2
antibody ch14.18/CHO in combination with interleukin‐2 in patients with high‐risk neuroblastoma
. Pediatric Blood & Cancer 65:6.
Crossref
Crossref
Vanessa P. Tolbert & Katherine K. Matthay. (2018) Neuroblastoma: clinical and biological approach to risk stratification and treatment. Cell and Tissue Research 372:2, pages 195-209.
Crossref
Crossref
Amy K. Erbe, Wei Wang, Lakeesha Carmichael, KyungMann Kim, Eneida A. Mendonça, Yiqiang Song, Dustin Hess, Patrick K. Reville, Wendy B. London, Arlene Naranjo, Jacquelyn A. Hank, Mitchell B. Diccianni, Ralph A. Reisfeld, Stephen D. Gillies, Katherine K. Matthay, Susan L. Cohn, Michael D. Hogarty, John M. Maris, Julie R. Park, M. Fevzi Ozkaynak, Andrew L. Gilman, Alice L. Yu & Paul M. Sondel. (2018) Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. Clinical Cancer Research 24:1, pages 189-196.
Crossref
Crossref
Juliet C. Gray & Paul M. Sondel. 2018. Immunotherapy for Pediatric Malignancies. Immunotherapy for Pediatric Malignancies
65
78
.
Francesco Ceppi, Maja Beck-Popovic, Jean-Pierre Bourquin & Raffaele Renella. (2017) Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot. European Journal of Pediatrics 176:9, pages 1163-1172.
Crossref
Crossref
Amanda Tivnan, Tatjana Heilinger, Joanne M. Ramsey, Gemma O’Connor, Jenny L. Pokorny, Jann N. Sarkaria, Brett W. Stringer, Bryan W. Day, Andrew W. Boyd, Ella L. Kim, Holger N. Lode, Sally-Ann Cryan & Jochen H.M. Prehn. (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:10, pages 16605-16620.
Crossref
Crossref
Julien Fleurence, Sophie Fougeray, Meriem Bahri, Denis Cochonneau, Béatrice Clémenceau, François Paris, Andras Heczey & Stéphane Birklé. (2017)
Targeting
O
-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
. Journal of Immunology Research 2017, pages 1-16.
Crossref
Crossref
Katherine K. Matthay, John M. Maris, Gudrun Schleiermacher, Akira Nakagawara, Crystal L. Mackall, Lisa Diller & William A. Weiss. (2016) Neuroblastoma. Nature Reviews Disease Primers 2:1.
Crossref
Crossref